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A disintegrin and metalloproteinase 10 (ADAM10) is a ubiquitous transmembrane pro-
tein that functions as a “molecular scissor” to cleave the extracellular regions from its 
transmembrane target proteins. ADAM10 is well characterized as the ligand-dependent 
activator of Notch proteins, which control cell fate decisions. Indeed, conditional knock-
outs of ADAM10 in mice reveal impaired B-, T-, and myeloid cell development and/
or function. ADAM10 cleaves many other leukocyte-expressed substrates. On B-cells, 
ADAM10 cleavage of the low-affinity IgE receptor CD23 promotes allergy and asthma, 
cleavage of ICOS ligand impairs antibody responses, and cleavage of the BAFF–APRIL 
receptor transmembrane activator and CAML interactor, and BAFF receptor, reduce 
B-cell survival. On microglia, increased ADAM10 cleavage of a rare variant of the scaven-
ger receptor triggering receptor expressed on myeloid cells 2 may increase susceptibility 
to Alzheimer’s disease. We and others recently showed that ADAM10 interacts with 
one of six different regulatory tetraspanin membrane proteins, which we termed the 
TspanC8 subgroup, comprising Tspan5, Tspan10, Tspan14, Tspan15, Tspan17, and 
Tspan33. The TspanC8s are required for ADAM10 exit from the endoplasmic reticulum, 
and emerging evidence suggests that they dictate ADAM10 subcellular localization and 
substrate specificity. Therefore, we propose that ADAM10 should not be regarded as a 
single scissor, but as six different scissors with distinct substrate specificities, depending 
on the associated TspanC8. In this review, we collate recent transcriptomic data to 
present the TspanC8 repertoires of leukocytes, and we discuss the potential role of the 
six TspanC8/ADAM10 scissors in leukocyte development and function.
Keywords: a disintegrin and metalloproteinase 10, tetraspanins, TspanC8s, leukocytes
inTRODUCTiOn
The proteolytic cleavage, or “shedding,” of the extracellular region (ectodomain) of transmembrane 
proteins is an important mechanism for the regulation of leukocyte development and function. 
Shedding can initiate intracellular signal transduction via the cell-associated cleavage fragment 
(e.g., Notch signaling to drive cell fate decisions), downregulate signaling or adhesion that requires 
cell surface receptor expression, or activate paracrine signaling through the release of growth fac-
tors, cytokines, and chemokines (1). The ADAMs (a disintegrin and metalloproteinases) are one 
FigURe 1 | Six ADAM10 scissors: Tspan14 and Tspan5 may be important for Notch activation in immune cells. (A) A schematic representation of a TspanC8 and 
ADAM10. (B) A model figure to show the six different TspanC8/ADAM10 complexes, which have different subcellular localizations, distinct substrate specificities, 
and may have different ADAM10 conformations. Notch cleavage is initiated following engagement with a Notch ligand on another cell (1), which induces a 
conformational change that we hypothesize allows cleavage by a Tspan14/ADAM10 or Tspan5/ADAM10 scissor (2), followed by intramembrane cleavage by 
γ-secretase (3), to release the intracellular domain to act as a transcription factor and drive cell fate decisions (4). Tspan10 has also been implicated in Notch 
activation, but its relatively low expression by immune cells suggests no substantial role in these cells. N-linked and O-linked glycosylation sites are indicated by  
filled ovals and short lines, respectively.
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of the main proteinase families that function as sheddases and 
can be regarded as “molecular scissors.” A total of 22 ADAM 
genes have been identified in humans, of which 12 (ADAM8, 
9, 10, 12, 15, 17, 19, 20, 21, 28, 30, and 33) are active proteases 
with the consensus sequence (HExGHxxGxxHD) required for 
Zn2+-dependent protease activity (1).
THe “MOLeCULAR SCiSSOR” ADAM10
One of the best-characterized ADAMs is ADAM10, due to its 
essential role in ligand-dependent cleavage of Notch proteins to 
initiate Notch signaling (2). Indeed, ADAM10-knockout mice die 
at embryonic day 9.5, phenocopying double knockout mice for 
two of the four Notch proteins, Notch 1 and 4 (3, 4). ADAM10 
has an N-terminal signal sequence, an inhibitory prodomain, a 
metalloproteinase domain, followed by disintegrin, cysteine-
rich, transmembrane, and cytoplasmic domains (Figure  1). 
The prodomain is removed by proprotein convertases during 
biosynthesis to generate a mature sheddase (5). The first crystal 
structure of the mature ADAM10 ectodomain suggests that the 
metalloprotease exists in a closed conformation in which the 
cysteine-rich domain partially occludes the catalytic site, but 
with the catalytic site in position to cleave substrates close to 
the plasma membrane (6). ADAM10 has at least 40 substrates, 
including amyloid precursor protein (7), cellular prion protein 
(8), cadherins (9–11), and the platelet-activating collagen/fibrin 
receptor GPVI (12, 13). ADAM10 has a number of substrates 
that are expressed by leukocytes, or which impact on leukocyte 
function, including the low-affinity IgE receptor CD23 (14, 15), 
the endothelial cell–cell adhesion molecule vascular-endothelial 
(VE)-cadherin (11), the B-cell costimulatory molecule ICOS 
ligand (16), B-cell homeostasis proteins transmembrane activator 
and CAML interactor (TACI) (17) and BAFF receptor (BAFFR) 
(18), and triggering receptor expressed on myeloid cells 2 
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(TREM2) (19, 20). ADAM10 has been implicated in myriad 
immune diseases including T-cell acute lymphoblastic leukemia 
(T-ALL), asthma, atherosclerosis, and Alzheimer’s disease (2).
TeTRASPAninS AS “MeMBRAne 
ORgAniZeRS”
The tetraspanins are a superfamily of transmembrane proteins 
expressed in multicellular eukaryotes. They are characterized by 
four transmembrane domains and small and large extracellular 
loops (Figure  1), the latter containing structurally important 
cysteine residues. Mammals express 33 tetraspanins and each 
cell type has a distinct repertoire of tetraspanins (21); leukocytes 
express at least 20 tetraspanins (22). Tetraspanins are “membrane 
organizers” that form dynamic nanoclusters (21). Visualization 
of tetraspanins CD37, CD53, CD81, and CD82 on human B-cells 
and dendritic cells, by super-resolution microscopy, suggests that 
approximately 10 tetraspanins of a single type cluster together 
into individual nanodomains (23). Tetraspanins also associate 
directly with specific non-tetraspanin proteins, termed “partner 
proteins,” to regulate their intracellular trafficking, clustering, 
lateral mobility, and compartmentalization (21). Relatively well-
studied tetraspanin–partner interactions are tetraspanin CD151 
with the laminin-binding integrins (24), tetraspanin CD81 with 
the B-cell co-receptor CD19 (25), and Tspan12 with the Wnt/
Norrin receptor Frizzled-4 (26). In each case, tetraspanin muta-
tions yield phenotypes that are consistent with impaired partner 
protein function. For example, in CD81-deficient humans and 
mice, CD19 fails to traffic to the B-cell surface and antibody 
generation is impaired (25). The recently published crystal 
structure of full-length CD81, which is the first such structure 
for a tetraspanin, shows CD81 to be cone shaped with an intram-
embrane cholesterol-binding cavity within the transmembranes 
(27). Molecular dynamics simulations suggest that CD81 may 
exist in two different conformations, a closed conformation 
when cholesterol is present, and an open conformation when 
cholesterol is absent, in which the large extracellular loop 
swings upwards (27). Therefore, tetraspanins could function as 
“molecular switches” that control the activity of their partner 
proteins through cholesterol-regulated conformational change.
TSPAnC8 TeTRASPAninS RegULATe 
ADAM10: THe “SiX SCiSSOR” 
HYPOTHeSiS
In 2012, we and others showed that ADAM10 interacts with 
six tetraspanins that are closely related by protein sequence: 
Tspan5, Tspan10, Tspan14, Tspan15, Tspan17, and Tspan33 
(28–30). We termed these the TspanC8 subgroup due to the eight 
cysteine residues in their large extracellular loops (28, 29); other 
tetraspanins have four, six, or seven cysteines. The TspanC8s are 
essential for promoting ADAM10 exit from the endoplasmic 
reticulum, its subsequent maturation in the Golgi through 
removal of the prodomain, and trafficking to the cell surface or 
other membrane compartments (28–30). The functional associa-
tion between TspanC8s and ADAM10 has been demonstrated in 
TspanC8-knockout mice (29, 31) and the fruit fly Drosophila (28), 
and is reinforced by recent data demonstrating reciprocal regula-
tion of Tspan5 exit from the endoplasmic reticulum by ADAM10 
(32). Moreover, emerging evidence indicates that each TspanC8 
can target ADAM10 to different subcellular localizations and to dif-
ferent substrates, and ADAM10 may adopt distinct conformations 
dictated by the associated TspanC8 (28, 32–35). For example, we 
and two other groups reported Tspan15 as the only TspanC8 to 
promote ADAM10 cleavage of neuronal (N)-cadherin (30, 33, 34). 
These in vitro data are supported by data from the recently char-
acterized Tspan15-deficient mouse, which has strikingly reduced 
N-cadherin cleavage in the brain, despite only a subtle decrease 
in mature ADAM10 expression (31). ADAM10 shedding of 
Notch is promoted by Tspan5, Tspan10, and Tspan14 (Figure 1), 
but not by Tspan15 and 33 (28, 32, 33, 36). In addition, we have 
shown Tspan5 and Tspan17 to regulate VE-cadherin expression 
on endothelial cells (35). Taking these data together, we now pro-
pose that ADAM10 should be regarded as six different TspanC8/
ADAM10 scissor complexes, rather than a single scissor (37, 38). 
This idea has implications for therapeutic targeting of ADAM10, 
which may be impractical due to toxic side effects. However, 
targeting one of the TspanC8/ADAM10 complexes, via the tet-
raspanin, may minimize toxicity while enabling substrate- and 
disease-specific targeting.
We and others have recently reviewed our current understan-
ding of how TspanC8s regulate ADAM10 (37–39). In this review, 
we will analyze and present published RNA-Seq transcriptomic 
data for TspanC8 expression in different leukocyte subsets. We 
will discuss these expression profiles in the context of our current 
knowledge of ADAM10’s role in the development and function of 
T-cells, B-cells, and myeloid cells.
RegULATiOn OF T-CeLL DeveLOPMenT 
AnD TRAnSMigRATiOn BY ADAM10 AnD 
TSPAnC8s
Two publications have shown that ADAM10 is important for 
normal T-cell development, most likely through regulation of 
Notch signaling (40, 41). In the first, the embryonic lethality of 
ADAM10-knockout mice was circumvented by the generation 
of transgenic mice that express dominant negative ADAM10 
under the control of the T-cell-specific Lck promoter (40). The 
dominant negative ADAM10 construct yields a similar pheno-
type to T-cell-specific deletion of Notch1, the Notch family mem-
ber with the major role in thymocyte development. Thymocyte 
numbers are reduced by 60–90% due to a partial block in the 
CD4/CD8 double negative to double positive transition, with 
accompanying reduction in expression of T-cell receptor (TCR) 
β (40). Defective Notch signaling is the probable mechanism, 
since expression of Notch-responsive genes is partially reduced, 
and partial rescue is achieved by transgenic overexpression of 
the Notch ligand Delta-1, or a dominant active form of Notch1, 
in thymocytes. The dominant negative construct lacks the 
metalloproteinase domain and is expressed at several-fold 
higher levels than endogenous ADAM10 (40); one mechanism 
of action may be the sequestration of endogenous TspanC8s, 
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since we have shown such a construct to interact with TspanC8s 
(34). In the second publication, conditional T-cell-specific 
ADAM10-knockout mice were generated by crossing ADAM10 
floxed mice with mice expressing Cre recombinase driven by 
the Lck promoter (41). This model phenocopies T-cell-specific 
Notch1 deletion in showing a twofold to threefold reduction 
in thymocyte numbers, due to a partial block in development 
from the double negative to double positive stage. There is 
reduced expression of Notch target genes but, unlike the domi-
nant negative ADAM10 model, no defect in TCRβ expression 
is observed (41).
The most highly expressed TspanC8 in human and mouse 
T-cells is Tspan14, followed by Tspan5 and Tspan17; Tspan15 is 
also expressed by human T-cells but not mouse (Figures 2A,B). 
However, it is important to note that such publically available 
transcriptomic data have not been independently validated, nor 
have the expression profiles been confirmed using validated 
antibodies. Nevertheless, since both Tspan14 and Tspan5 pro-
mote Notch signaling (28, 32, 33), we hypothesize that Tspan14/
ADAM10 will have a major role in thymocyte development via 
activation of Notch1, while Tspan5/ADAM10 may have a minor 
role. The future analyses of the respective knockout mice will 
help to test this hypothesis; the Tspan14-knockout mouse has 
yet to be made, while the Tspan5-knockout mouse is viable but 
functionally uncharacterized (32). It is possible that Tspan14 
and/or Tspan5 play a role in the aggressive blood cancer T-ALL. 
Approximately 50% of T-ALL is driven by activating mutations 
in Notch1, some of which require ADAM10 for full activation in 
a ligand-independent manner. Knockdown of ADAM10 reduces 
Notch signaling and T-ALL proliferation (42). Targeting Tspan14 
or Tspan5 may achieve a similar result, yet without the toxicity of 
global ADAM10 inhibition. Interestingly, antibody targeting of 
Tspan5 can impair Notch signaling (32).
In addition to Notch proteins, a number of other proteins 
have been reported to be cleaved by ADAM10 on T-cells: CD40 
ligand (44), Fas ligand (45, 46), LAG-3 (47), CD44 (48), and 
T-cell immunoglobulin and mucin domain 3 (Tim-3) (49). How 
important these cleavage events are to T-cell function has yet to 
be determined, and for CD40 ligand, LAG-3 and Tim-3 is com-
plicated by their additional cleavage by ADAM17 (44, 47, 49), an 
ADAM10-related metalloproteinase.
We have recently reported that endothelial cell-expressed 
ADAM10 promotes the transmigration (also known as extrava-
sation or diapedesis) of T-cells in an in vitro model of inflam-
mation (35). The mechanism involves ADAM10 regulation of 
VE-cadherin expression levels, since ADAM10 knockdown 
results in 50% elevated VE-cadherin expression and delayed 
transmigration, which is rescued by partial VE-cadherin 
knockdown to wild-type levels. This promotion of transmigra-
tion by endothelial ADAM10 appears restricted to T-cells, since 
no effects on neutrophils or B-cell transmigration are observed 
(35), nor on monocytes in a separate study (50). Among the 
TspanC8s, we have previously reported that Tspan14 is the 
most highly expressed on endothelial cells (29, 51). However, 
knockdown experiments show that Tspan5 and Tspan17 are the 
tetraspanins that promote ADAM10 regulation of VE-cadherin 
(35). Consistent with this common function, Tspan5 and 
Tspan17 are the most highly conserved pair of tetraspanins, 
with 72% protein sequence identity in human (35). However, 
it remains to be determined whether this role for Tspan5/17 
holds true in vivo. Tspan17-knockout mice have yet to be made; 
ultimately a Tspan5/17 double knockout may be required to 
overcome functional redundancy.
RegULATiOn OF B-CeLL DeveLOPMenT 
AnD FUnCTiOn BY ADAM10 AnD 
POTenTiAL ROLe FOR TSPAnC8s
An important role for ADAM10 in B-cell development and 
function has been demonstrated using B-cell-specific ADAM10-
knockout mice, made by crossing ADAM10 floxed mice with 
CD19-Cre mice (52). Early development of B-cells in the bone 
marrow of these mice is unaltered, with normal numbers of pro-, 
pre-, and immature B-cell populations. B1 cell numbers in the 
peritoneal cavity are also normal. However, ADAM10-knockout 
immature B-cells entering the spleen fail to develop into marginal 
zone B-cells; these cells act as a first line of defense by rapid antibody 
generation against blood-borne pathogens that become trapped 
in the spleen. By contrast, follicular zone B-cell numbers in the 
spleen are slightly elevated. The mechanism underlying defective 
marginal zone B-cell development in the absence of ADAM10 
appears to be defective Notch2 activation (52), and consistent 
with this, B-cells express relatively high levels of Notch2 and low 
levels of Notch 1, 3, and 4, and Notch2 is critical for development 
of marginal zone but not follicular B-cells (53–55).
B-cell-specific ADAM10-knockout mice have a striking 
reduction in antibody responses following immunization, 
associated with impaired germinal center formation in second-
ary lymphoid tissues (56). The mechanism responsible appears 
to be the upregulated expression of TNFα, a pro-inflammatory 
cytokine which is important for the maintenance of lymphoid 
tissue architecture, and ADAM17, which sheds TNFα (57). How 
ADAM10-deficiency leads to ADAM17 and TNFα upregula-
tion in B-cells remains unknown. To investigate the function 
of ADAM10-knockout plasma cells in the context of normal 
germinal centers, ADAM10 floxed mice were crossed with IgG1-
Cre mice to delete ADAM10 post-isotype switching. Antibody 
responses are strikingly reduced, despite normal plasma cell 
numbers (58). This may be due to elevated expression of ICOS 
ligand, a recently identified ADAM10 substrate, on ADAM10-
knockout B-cells (16). The engagement of ICOS ligand with its 
receptor ICOS on T-cells is required for T-cell-dependent anti-
body responses. In ADAM10-knockout B-cells, elevated ICOSL 
causes a substantial reduction in surface ICOS by promoting its 
internalization (16), thus providing a mechanism for impaired 
antibody responses.
With the possible exception of Notch2, the best-studied 
ADAM10 substrate on B-cells is CD23, the low-affinity IgE 
receptor, which regulates allergic and inflammatory responses 
(14, 15). Indeed, on ADAM10-knockout B-cells, CD23 expression 
is increased approximately threefold, while soluble CD23 levels 
in plasma are substantially reduced (52). In an IgE-dependent 
asthma model, B-cell-specific ADAM10-knockout mice have 
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FigURe 2 | Continued
FigURe 2 | Leukocytes express ADAM10, but different cell subsets have distinct TspanC8 repertoires. Publically available RNA-Seq data for (A) human  
leukocytes [Gene Expression Omnibus (GEO) accession GSE51984], (B) mouse T-cell subsets (43), (C) mouse B-cells (GEO accession GSE60927), and (D) mouse 
macrophages, monocytes, and neutrophils (GEO accession GSE59831). Data are presented as reads per kilobase of transcript per million mapped reads (RPKM) 
(A,C), as length-adjusted values that provide a measure equivalent to RPKM (43) (B), or as fragments per kilobase of transcript per million mapped reads (FPKM) 
(D). Error bars represent the SD. Number of samples are as follows: five for panel (A), except for CD34+ peripheral cells (hematopoietic stem cells from the  
blood) which has one; two for panel (C), except for splenic plasmablasts and bone marrow plasma cells which have one, and splenic plasma cells which  
have three; and two for panel (D), with the exception of neutrophils which have two.
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strikingly reduced signs of allergic inflammation in the lung 
(59). Allergic patients and allergy-prone Th2 mice have increased 
expression of ADAM10 on B-cells and increased soluble CD23 
and IgE levels in plasma (60). Although the regulation of IgE 
expression by CD23 is complex and not fully understood, these 
data have lead the authors to propose ADAM10 as a therapeutic 
target for asthma (59).
ADAM10 is emerging as a regulator of the BAFF–APRIL 
system which controls B-cell homeostasis. The two ligands are 
BAFF and APRIL, while the three receptors are B-cell matura-
tion antigen, TACI, and BAFFR, the latter of which binds BAFF 
but not APRIL. ADAM10 can shed TACI to release a soluble 
ectodomain that acts as a decoy receptor, binding to BAFF and 
APRIL and so inhibiting survival of B-cells (17). In addition, cell 
survival can be reduced by ADAM10 or ADAM17 shedding of 
BAFFR (18).
In human B-cells, Tspan33 expression is highest, followed 
by Tspan14, Tspan17, and then Tspan5 (Figure 2A). In mouse, 
Tspan14 expression is highest, followed by Tspan5, Tspan15, 
and Tspan17, while Tspan33 expression is minimal (Figure 2C). 
Therefore, Tspan14 is likely to be the main regulator of Notch2 
in B-cells, with a less important role for Tspan5. A role for 
TspanC8s in regulating CD23 shedding has not been reported, 
but Tspan5, Tspan14, Tspan17, and/or Tspan33 are candidates; 
this is important work for the future, because such a tetraspanin 
is a potential therapeutic target for asthma. Tspan33 expression 
in human B-cells has been confirmed at the protein level (61), 
but the ADAM10 substrates that it regulates have not been 
investigated.
RegULATiOn OF MYeLOiD CeLL 
FUnCTiOn BY ADAM10 AnD POTenTiAL 
ROLe FOR TSPAnC8s
Dendritic cell-specific ADAM10-knockout mice have been 
generated by crossing ADAM10 floxed mice with CD11c-Cre 
mice (62). These mice have strikingly impaired Th2 responses, 
but Th1 and Th17 responses are unaffected. As a consequence, 
the mice are protected from IgE-mediated anaphylaxis and 
allergic lung inflammation. This appears to be due to defec-
tive Notch signaling, since rescue is observed by transgenic 
expression of the Notch1 intracellular domain, and dendritic 
cell-specific Notch1-knockout mice have a similar phenotype 
(62). Our RNA-Seq analyses have found Tspan14 to be most 
highly expressed in human dendritic cells, with lower expres-
sion of Tspan17 and Tspan33 (data not shown). Therefore, 
Tspan14 is likely to be important in dendritic cells for Notch 
signaling.
Specific knockout of ADAM10 in myeloid cells has been 
investigated by crossing ADAM10 floxed mice with LysM-cre 
mice (63). This does not achieve complete knockout in myeloid 
cells, but surface levels of ADAM10 on bone marrow-derived 
macrophages are reduced by 85%. No major abnormalities in the 
mice are observed, and leukocyte populations are present in nor-
mal numbers. However, ADAM10-knockout results in a reduced 
inflammatory phenotype in macrophages and a reduced capacity 
to migrate and to degrade extracellular matrix (63). Macrophages 
play a central role in the initiation and progression of the inflam-
matory disease atherosclerosis, and can take up lipids to become 
pro-inflammatory foam cells within atherosclerotic plaques. To 
investigate the role of macrophage ADAM10 in this disease, bone 
marrow from myeloid-specific ADAM10-knockout mice was 
transplanted into atherosclerosis-prone low-density lipoprotein 
receptor knockout mice. Consistent with a less inflammatory 
macrophage phenotype, atherosclerotic plaques appear more sta-
ble, with higher collagen content, although plaque size is similar 
to wild type (63). Nevertheless, this has important implications 
for human disease; stable plaques are less susceptible to the rup-
ture that causes thrombosis, vessel occlusion, and heart attack or 
stroke. Interestingly, Notch signaling promotes an inflammatory 
macrophage phenotype, and blockade of Notch signaling in an 
atherosclerosis model reduces atherosclerosis development while 
increasing plaque stability (64). Macrophages express relatively 
high levels of the Notch-promoting Tspan14 (Figures  2A,D), 
highlighting the macrophage Tspan14/ADAM10 complex as a 
potential therapeutic target for maintaining plaque stability in 
atherosclerosis.
An additional study generated mice with leukocyte- and mye-
loid-specific ADAM10 deficiency by crossing floxed ADAM10 
mice with Vav-Cre and LysM-Cre mice, respectively. In an 
inflammatory lung model, neutrophil and monocyte recruitment 
are reduced by approximately 50% in the absence of ADAM10 
(65). The underlying mechanism is not clear. Tspan14 appears 
to be the only TspanC8 expressed by human granulocytes and is 
also highly expressed by mouse neutrophils, which have relatively 
weak Tspan5 expression (Figures  2A,D). Therefore, Tspan14/
ADAM10-induced Notch activation may potentially promote 
neutrophil inflammatory responses.
Finally, the scavenger receptor TREM2 has been recently iden-
tified as an ADAM10 substrate with a potential role in Alzheimer’s 
disease (19, 20). TREM2 is expressed on macrophages, microglia, 
osteoclasts, and dendritic cells. A rare H157Y variant of TREM2 
is associated with increased risk of Alzheimer’s disease; amino 
acid 157 is at the cleavage site for ADAM10, and H157Y is 
shed more readily. The loss of TREM2 renders macrophages 
less phagocytic, and the authors propose that this renders the 
individual more prone to Alzheimer’s disease (19, 20). It will be 
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interesting to determine if any macrophage-expressed TspanC8, 
namely Tspan5, Tspan14, Tspan17, or Tspan33, can promote 
TREM2 cleavage, and could thus be considered a therapeutic 
target for TREM2-associated Alzheimer’s disease.
COnCLUDing ReMARKS
The six scissor hypothesis suggests that ADAM10 should be stud-
ied in the context of its regulatory tetraspanins. In leukocytes, the 
relatively high expression of Tspan14, together with its capacity 
to promote Notch activation, suggest that the Tspan14/ADAM10 
complex may be critical for leukocyte development and function. 
The future analyses of cells and mice deficient in Tspan14, and 
other TspanC8s, will determine which scissor cleaves which 
substrates. This may direct therapeutic targeting of individual 
TspanC8/ADAM10 complexes, using antibodies or small mol-
ecules, to modulate a specific substrate while avoiding the toxicity 
of global ADAM10 targeting. Such an approach could provide 
new treatments for ADAM10-associated diseases, including 
T-ALL, asthma, atherosclerosis, and Alzheimer’s disease.
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